XPH - ETF AI Analysis

Top Page

SPDR S&P Pharmaceuticals ETF (XPH)

Rating:59Neutral

Price Target:―

XPH, the SPDR S&P Pharmaceuticals ETF, has a solid but not top-tier rating, reflecting a mix of strong blue-chip pharma names and riskier biotech holdings. High-quality companies like Merck (MRK) and Johnson & Johnson (JNJ), with robust financial performance, attractive outlooks, and supportive technical trends, help lift the fund’s overall quality. However, weaker, pre-revenue or loss-making biotech names such as MBX Biosciences (MBX), Edgewise Therapeutics (EWTX), and Mind Medicine (DFTX) introduce higher risk and volatility, and the fund’s focus on the pharmaceutical and biotech space means it is concentrated in one sector.

Positive Factors

Strong Recent Top Holdings

Many of the largest positions, such as MBX Biosciences, Definium Therapeutics, Organon, and Amylyx Pharmaceuticals, have shown strong year-to-date gains, helping support the fund’s overall performance.

Solid Recent Performance Momentum

The ETF has delivered strong returns over the last three months and slightly positive results year-to-date, indicating improving momentum after a recent dip.

Reasonable Expense Ratio for a Niche Sector

The fund’s expense ratio is moderate for a specialized pharmaceuticals ETF, so investors are not paying unusually high ongoing fees for this focused exposure.

Negative Factors

Highly Concentrated in Health Care

With almost all assets in the health care sector, the fund is heavily exposed to industry-specific risks like regulatory changes and drug approval setbacks.

Limited Geographic Diversification

The ETF is almost entirely invested in U.S. companies, offering little protection if the U.S. market or domestic pharmaceutical industry faces a downturn.

Small Asset Base

The relatively modest assets under management may lead to lower trading volumes and wider bid-ask spreads, which can increase trading costs for investors.

XPH vs. SPDR S&P 500 ETF (SPY)

AUM317.79M

RegionNorth America

Expense Ratio0.35%

Beta0.75

IssuerSPDR

Inception DateJun 19, 2006

Dividend Yield0.84%

Asset ClassEquity

Index TrackedS&P Pharmaceuticals Select Industry

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume66,504

30 Day Avg. Volume105,261

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

89.65

Price Target Upside― Downside

Rating ConsensusStrong Buy

Number of Analyst Covering58

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

XPH Summary

SPDR S&P Pharmaceuticals ETF (XPH) is a fund that follows the S&P Pharmaceuticals Select Industry Index, focusing on U.S. drugmakers of many sizes. It holds a mix of well-known companies like Merck alongside smaller, more specialized pharmaceutical firms working on new treatments and medicines. Someone might invest in XPH to bet on long-term growth in health care and pharmaceuticals, while still spreading money across many companies instead of picking just one stock. A key risk is that it is heavily focused on the pharmaceutical industry, so its price can swing with drug trial results, regulation changes, and health care policy.

How much will it cost me?The SPDR S&P Pharmaceuticals ETF (XPH) has an expense ratio of 0.35%, which means you’ll pay $3.50 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is a sector-focused fund, which often requires more active management compared to broad-market index funds.

What would affect this ETF?The SPDR S&P Pharmaceuticals ETF (XPH) could benefit from increasing global health care needs, advancements in biotechnology, and demographic trends such as aging populations, which drive demand for innovative drugs and treatments. However, it may face challenges from regulatory changes, patent expirations, or pricing pressures in the pharmaceutical industry, as well as broader economic conditions like rising interest rates that could impact funding for smaller companies in its portfolio. Its focus on U.S.-based pharmaceutical firms makes it sensitive to domestic health care policies and market dynamics.

XPH Top 10 Holdings

XPH is a pure play on U.S. pharma, blending steady giants with punchy smaller drug developers. Blue-chip anchors like Merck and Johnson & Johnson are quietly rising, providing the fund with a solid, defensive backbone. Around them, names like Nektar Therapeutics and Viatris are doing the heavy lifting lately, with strong upward momentum that’s helping drive performance. On the flip side, early-stage players such as MBX Biosciences and Edgewise Therapeutics have been more mixed, occasionally tripping up returns and reminding investors this pharma basket isn’t risk-free.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
DFTX	Definium Therapeutics	2.73%	$8.68M	$1.76B	158.56%	40 Neutral
NKTR	Nektar Therapeutics	2.42%	$7.68M	$1.98B	436.83%	47 Neutral
VTRS	Viatris	2.41%	$7.67M	$16.30B	46.74%	60 Neutral
EWTX	Edgewise Therapeutics	2.30%	$7.32M	$2.98B	-0.68%	40 Underperform
RPRX	Royalty Pharma	2.30%	$7.31M	$26.20B	37.56%	79 Outperform
MRK	Merck & Company	2.29%	$7.28M	$286.28B	22.33%	80 Outperform
BMY	Bristol-Myers Squibb	2.29%	$7.26M	$122.78B	-1.31%	78 Outperform
SUPN	Supernus Pharmaceuticals	2.27%	$7.19M	$3.10B	67.98%	55 Neutral
JNJ	Johnson & Johnson	2.24%	$7.10M	$579.34B	44.22%	78 Outperform
PAHC	Phibro Animal Health	2.22%	$7.06M	$1.94B	102.71%	64 Neutral

XPH Technical Analysis

Technical Analysis Sentiment

Neutral

Last Price―

Price Trends

50DMA

56.61

Negative

100DMA

54.14

Positive

200DMA

48.96

Positive

Market Momentum

MACD

-0.15

Positive

RSI

39.19

Neutral

STOCH

23.58

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XPH, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 57.08, equal to the 50-day MA of 56.61, and equal to the 200-day MA of 48.96, indicating a neutral trend. The MACD of -0.15 indicates Positive momentum. The RSI at 39.19 is Neutral, neither overbought nor oversold. The STOCH value of 23.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for XPH.

XPH Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
XPH	―	―	$317.79M	0.35%	59 Neutral
FXH	―	―	$885.15M	0.61%	71 Outperform
RSPH	―	―	$749.39M	0.40%	71 Outperform
IHF	―	―	$718.87M	0.38%	69 Neutral
PJP	―	―	$406.98M	0.57%	69 Neutral
PINK	―	―	$259.04M	0.51%	66 Neutral

Performance Comparison

XPH

SPDR S&P Pharmaceuticals ETF

55.16

11.77

27.13%

FXH

First Trust Health Care AlphaDEX Fund

―

RSPH

Invesco S&P 500 Equal Weight Health Care ETF

―

IHF

iShares U.S. Healthcare Providers ETF

―

PJP

Invesco Dynamic Pharmaceuticals ETF

―

PINK

Simplify Health Care ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents